AI Bias Analysis
4 models · Takes ~15 seconds
Neurocrine Biosciences is buying Soleno Therapeutics for $2.9 billion, picking up an approved medicine for a rare disease that causes insatiable hunger.
Source
Stat News
Opens original article in a new tab
A small biotech was forced to being winding down its operations after the FDA abruptly postponed a key meeting for four months
How thin science fuels peptide hype, blowback to proposed NIH cuts, and more biotech news from The Readout
A hep B trial raises ethical questions, the peptide hype, and more Morning Rounds news
In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The agreement came four months too late.